Prosecution Insights
Last updated: April 19, 2026
Application No. 18/598,617

METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF

Non-Final OA §DP
Filed
Mar 07, 2024
Examiner
LEWIS, PATRICK T
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Queen's University of Belfast
OA Round
2 (Non-Final)
74%
Grant Probability
Favorable
2-3
OA Rounds
2y 6m
To Grant
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
844 granted / 1135 resolved
+14.4% vs TC avg
Moderate +14% lift
Without
With
+14.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
40 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
30.5%
-9.5% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1135 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s Response Dated September 23, 2025 In the Response dated September 23, 2025, no claim was amended, added, or canceled. Claims 1-46 are pending. An action on the merits of claims 1-46 is contained herein. The rejection of claims 1-46 under 35 U.S.C. 101 as claiming the same invention as that of claims 1-23 and 25-44 of prior U.S. Patent No. 11,981,698 B2 has been withdrawn in view of applicant’s argument that the claims are not coextensive in scope. The rejection of claims 1-4, 6, 10-23, 25, 28, 31-35, 37-40, and 43 on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 of U.S. Patent No. 10,280,190 B2 is maintained for the reasons of record as set forth in the Office Action dated April 23, 2025. The rejection of claims 1-8 and 10-43 on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 and 14-20 of U.S. Patent No. 10,815,262 B2 has been rendered moot in view of the Terminal Disclaimer filed September 23, 2025. The rejection of claims 1-8 and 10-43 on the ground of nonstatutory double patenting as being unpatentable over claims 4-13 and 18-19 of U.S. Patent No. 11,584,770 B2 has been rendered moot in view of the Terminal Disclaimer filed September 23, 2025. Rejections Set Forth in the Office Action Dated April 23, 2025 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-4, 6, 10-23, 25, 28, 31-35, 37-40, and 43 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 of U.S. Patent No. 10,280,190 B2. Applicant's arguments filed September 23, 2025 have been fully considered but they are not persuasive. Applicant argues that the ‘190 patent does not qualify as prior art. Applicant’s argument has been fully considered; however, the argument is not germane. The ‘190 patent and the instant application have at least one common inventor and a common assignee. Thus, the rejection is maintained for the reasons of record. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-43 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 and 25-44 of prior U.S. Patent No. 11,981,698 B2. Although the conflicting claims are not identical, they are not patentably distinct from each other because the only difference between the claims is that the instant claims depict stereoisomers; however, a prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties. Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. Conclusion Claims 1-46 are pending. Claims 1-43 are rejected. Claims 44-46 are allowed. Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Deirdre Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Mar 07, 2024
Application Filed
Apr 18, 2025
Non-Final Rejection — §DP
Sep 23, 2025
Response Filed
Jan 07, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599594
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
2y 5m to grant Granted Apr 14, 2026
Patent 12599595
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
2y 5m to grant Granted Apr 14, 2026
Patent 12595281
Indodicarbocyanine Phosphoramidites with Bathochromically Shifted Absorption and Emission, and Tunable Hydrophobicity
2y 5m to grant Granted Apr 07, 2026
Patent 12594292
ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS
2y 5m to grant Granted Apr 07, 2026
Patent 12584124
MAGNETIC BEAD BASED NUCLEIC ACID EXTRACTION SYSTEM
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.3%)
2y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 1135 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month